|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Ｒｇｍおよびそのモジュレーターの用途
|
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
|
EP2033971A1
(de)
*
|
2007-09-06 |
2009-03-11 |
Abbott GmbH & Co. KG |
Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
|
|
US20090162359A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
|
GEP20156390B
(en)
|
2008-01-03 |
2015-11-10 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain
|
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
|
US8962803B2
(en)
*
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
HRP20180045T1
(hr)
|
2008-10-02 |
2018-03-23 |
Aptevo Research And Development Llc |
Proteini antagonisti cd86 koji se vežu na više meta
|
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
DK2417156T3
(en)
|
2009-04-07 |
2015-03-02 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
|
RU2570633C2
(ru)
*
|
2009-05-27 |
2015-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Три- или тетраспецифические антитела
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110172398A1
(en)
*
|
2009-10-02 |
2011-07-14 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules for anti-angiogenesis therapy
|
|
CA2777242A1
(en)
*
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
|
KR20120118002A
(ko)
*
|
2009-12-08 |
2012-10-25 |
애보트 게엠베하 운트 콤파니 카게 |
망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
|
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
|
EP2519544A1
(en)
*
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Polypeptide heterodimers and uses thereof
|
|
TWI426920B
(zh)
*
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
UY33492A
(es)
*
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2593142B8
(en)
|
2010-07-12 |
2018-12-26 |
Pfizer Healthcare Ireland |
Multifunctional antibody conjugates
|
|
WO2012009705A1
(en)
*
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
JP2013538338A
(ja)
|
2010-07-19 |
2013-10-10 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
|
SG10201505593VA
(en)
|
2010-07-19 |
2015-09-29 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102372778B
(zh)
*
|
2010-08-19 |
2015-06-17 |
上海抗体药物国家工程研究中心有限公司 |
抗人vegf和opn双特异性抗体、其制备方法及用途
|
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
JP5764677B2
(ja)
|
2011-02-28 |
2015-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原結合タンパク質
|
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
|
ES2865449T3
(es)
|
2011-03-16 |
2021-10-15 |
Hoffmann La Roche |
Cromatografía de intercambio iónico con selectividad mejorada para la separación de monómeros, agregados y fragmentos polipeptídicos por modulación de la fase móvil
|
|
BR112013023653A2
(pt)
|
2011-03-17 |
2016-12-13 |
Univ Ramot |
anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
|
|
US9527925B2
(en)
*
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
US20130078247A1
(en)
*
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
|
TWI577696B
(zh)
*
|
2011-10-20 |
2017-04-11 |
Ｅｓｂａ科技 諾華有限責任公司 |
穩定的多重抗原結合抗體
|
|
CN110078831A
(zh)
|
2011-12-01 |
2019-08-02 |
圆祥生命科技股份有限公司 |
补体和vegf途径的蛋白质抑制剂及其使用方法
|
|
CN102936277B
(zh)
*
|
2011-12-29 |
2014-10-01 |
北京五康新兴科技有限公司 |
人血管内皮生长因子抗原表位及其表位疫苗
|
|
PE20190907A1
(es)
|
2012-01-27 |
2019-06-26 |
AbbVie Deutschland GmbH and Co KG |
Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
|
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
|
SI2814587T1
(en)
|
2012-02-15 |
2018-08-31 |
F. Hoffmann-La Roche Ag |
Affinity chromatography based on the Fc receptor
|
|
US20150110788A1
(en)
*
|
2012-03-06 |
2015-04-23 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
CN104487587A
(zh)
|
2012-04-20 |
2015-04-01 |
新兴产品开发西雅图有限公司 |
Cd3结合多肽
|
|
TW201823460A
(zh)
|
2012-05-29 |
2018-07-01 |
美商再生元醫藥公司 |
生產細胞株增強子
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
WO2014009474A1
(en)
|
2012-07-13 |
2014-01-16 |
F. Hoffmann-La Roche Ag |
Method for the detection of a multispecific binder
|
|
WO2014034735A1
(ja)
*
|
2012-08-31 |
2014-03-06 |
国立大学法人 大阪大学 |
Ｖｅｇｆ及び／又はアンギオポエチン－２の特異的エピトープを含むｄｎａワクチン
|
|
JP2015532272A
(ja)
*
|
2012-09-28 |
2015-11-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
|
|
MX2015003894A
(es)
*
|
2012-09-28 |
2015-07-17 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 agentes anti-vegf.
|
|
SI2914612T1
(sl)
|
2012-10-30 |
2019-03-29 |
F. Hoffmann-La Roche Ag |
Čiščenje polipeptidov z uporabo dvostopenjske tangencialne ultrafiltracije
|
|
HK1212359A1
(en)
|
2012-11-01 |
2016-06-10 |
Abbvie Inc. |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
JP2016528167A
(ja)
*
|
2013-04-29 |
2016-09-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ヒトＦｃＲｎ結合改変抗体及び使用方法
|
|
KR102266819B1
(ko)
*
|
2013-04-29 |
2021-06-18 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
|
|
KR102131371B1
(ko)
|
2013-07-02 |
2020-07-08 |
삼성전자주식회사 |
Ang-2 특이적 항체 및 그의 용도
|
|
CN105518028B
(zh)
*
|
2013-07-09 |
2019-08-13 |
Abl生物公司 |
与dll4和vegf特异性结合的新型双靶向蛋白及其用途
|
|
KR102060187B1
(ko)
|
2013-07-19 |
2019-12-27 |
삼성전자주식회사 |
Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
|
|
JP6463361B2
(ja)
|
2013-09-08 |
2019-01-30 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
CN103604923B
(zh)
*
|
2013-10-22 |
2015-05-13 |
卫生部北京医院 |
检测抗甲状腺过氧化物酶和甲状腺球蛋白的天然双特异性抗体的试剂盒
|
|
KR102178323B1
(ko)
*
|
2013-11-29 |
2020-11-13 |
삼성전자주식회사 |
항 c-Met/항 Ang2 이중 특이 항체
|
|
KR20160098239A
(ko)
*
|
2013-12-13 |
2016-08-18 |
에프. 호프만-라 로슈 아게 |
다가, 다중특이적 분자의 생물 활성을 확인하기 위한 ｓｐｒ-기반 가교 검정법
|
|
KR20160085888A
(ko)
*
|
2013-12-20 |
2016-07-18 |
에프. 호프만-라 로슈 아게 |
항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
|
|
RU2698969C2
(ru)
*
|
2014-01-15 |
2019-09-02 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с улучшенной способностью связываться с белком а
|
|
AR100271A1
(es)
|
2014-05-19 |
2016-09-21 |
Lilly Co Eli |
Compuestos de vegfr2 / ang2
|
|
WO2015200905A2
(en)
*
|
2014-06-28 |
2015-12-30 |
Oligasis, Llc |
Dual pdgf/vegf antagonists
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
WO2016016299A1
(en)
*
|
2014-07-29 |
2016-02-04 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
KR102390359B1
(ko)
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
|
EP3215524B1
(en)
*
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
CA2963606A1
(en)
*
|
2014-11-10 |
2016-05-19 |
F.Hoffmann-La Roche Ag |
Anti-ang2 antibodies and methods of use
|
|
WO2016075034A1
(en)
|
2014-11-10 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
|
|
SG11201703428SA
(en)
|
2014-11-10 |
2017-05-30 |
Hoffmann La Roche |
Bispecific antibodies and methods of use in ophthalmology
|
|
AU2015345322A1
(en)
|
2014-11-10 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-PDGF-B antibodies and methods of use
|
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
AR103477A1
(es)
|
2015-01-28 |
2017-05-10 |
Lilly Co Eli |
Compuestos de vegfa / ang2
|
|
CN104818295A
(zh)
*
|
2015-02-03 |
2015-08-05 |
武汉友芝友生物制药有限公司 |
制备和筛选表达双特异性抗体细胞株的方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN107849126B
(zh)
*
|
2015-07-29 |
2022-04-08 |
阿勒根公司 |
仅有重链的抗ang-2抗体
|
|
WO2017048699A2
(en)
*
|
2015-09-14 |
2017-03-23 |
Galaxy Biotech Llc |
Highly potent monoclonal antibodies to angiogenic factors
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
EP3150637A1
(en)
*
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
EP3356420B1
(en)
*
|
2015-10-02 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
SG11201803732PA
(en)
*
|
2015-11-30 |
2018-06-28 |
Pieris Australia Pty Ltd |
Novel anti-angiogenic fusion polypeptides
|
|
WO2017117464A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
|
KR102293753B1
(ko)
|
2016-01-06 |
2021-08-24 |
오더-메이드 메디컬 리서치 인코포레이티드 |
Vegf 와 nrp1 의 결합을 저해하는 항체
|
|
EP3401331B1
(en)
*
|
2016-01-06 |
2022-04-06 |
Order-Made Medical Research Inc. |
High-affinity anti-vegf antibody
|
|
US10894823B2
(en)
*
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
WO2018007314A1
(en)
*
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
|
WO2018017714A1
(en)
|
2016-07-20 |
2018-01-25 |
Aerpio Therapeutics, Inc. |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
CN109863171B
(zh)
*
|
2016-08-23 |
2023-08-04 |
免疫医疗有限公司 |
抗vegf-a和抗ang2抗体及其用途
|
|
WO2018114728A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
|
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
CN108659112B
(zh)
*
|
2017-03-30 |
2021-01-26 |
上海市同济医院 |
一种非对称双特异性抗体
|
|
BR112019017241A2
(pt)
*
|
2017-04-13 |
2020-04-14 |
Agenus Inc |
anticorpos anti-cd137 e métodos de uso dos mesmos
|
|
EP3630822A1
(en)
|
2017-06-02 |
2020-04-08 |
Boehringer Ingelheim International GmbH |
Anti-cancer combination therapy
|
|
MX2020007527A
(es)
|
2018-02-06 |
2020-09-09 |
Hoffmann La Roche |
Tratamiento de enfermedades oftalmologicas.
|
|
BR112020017872A2
(pt)
|
2018-03-02 |
2020-12-22 |
Kodiak Sciences Inc. |
Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
|
|
MX2020010728A
(es)
*
|
2018-04-13 |
2020-11-06 |
Affimed Gmbh |
Constructos de fusion de anticuerpos que se acoplan a celulas nk.
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
US12493033B2
(en)
|
2018-06-04 |
2025-12-09 |
Chugai Seiyaku Kabushiki Kaisha |
Method for detecting bi-specific antibody complex
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
WO2020006516A1
(en)
*
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
AU2019299110B2
(en)
*
|
2018-07-03 |
2025-07-17 |
Catalent Pharma Solutions, Llc |
Multifunctional protein molecules comprising decorin and use thereof
|
|
CN112512581B
(zh)
*
|
2018-08-03 |
2024-12-17 |
安进研发（慕尼黑）股份有限公司 |
针对cldn18.2和cd3的抗体构建体
|
|
WO2020037309A1
(en)
*
|
2018-08-17 |
2020-02-20 |
Trican Biotechnology Co., Ltd. |
Anti-angiogenesis fusion protein and uses thereof
|
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
|
US10894824B2
(en)
*
|
2018-09-24 |
2021-01-19 |
Aerpio Pharmaceuticals, Inc. |
Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
US20220185875A1
(en)
*
|
2019-03-18 |
2022-06-16 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific antibody specifically bound to vegf and ang2
|
|
WO2020254351A1
(en)
|
2019-06-19 |
2020-12-24 |
F. Hoffmann-La Roche Ag |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
CA3140318A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
EP4010370A1
(en)
*
|
2019-08-06 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Personalized treatment of ophthalmologic diseases
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
WO2021072265A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CN114901700B
(zh)
*
|
2019-11-21 |
2025-04-22 |
尤尼蒂生物技术公司 |
针对tie-2的抗体及其使用方法
|
|
CN120757643A
(zh)
|
2020-03-24 |
2025-10-10 |
基因泰克公司 |
Tie2结合剂及其使用方法
|
|
US20230242633A1
(en)
|
2020-07-07 |
2023-08-03 |
Kanaph Therapeutics Inc. |
Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof
|
|
WO2022008699A1
(en)
*
|
2020-07-09 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Concentrated compositions of proteins, their preparation and use thereof
|
|
KR20230066317A
(ko)
*
|
2020-07-10 |
2023-05-15 |
바이오몰레큘러 홀딩스 엘엘씨 |
사면체 항체
|
|
CN114106190B
(zh)
*
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
WO2022057888A1
(zh)
*
|
2020-09-17 |
2022-03-24 |
江苏恒瑞医药股份有限公司 |
特异性结合vegf和ang-2的双特异性抗原结合分子
|
|
AR123862A1
(es)
*
|
2020-10-21 |
2023-01-18 |
Boehringer Ingelheim Int |
Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
|
|
JP2024515220A
(ja)
|
2021-04-26 |
2024-04-05 |
セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー |
高分子薬剤化合物の持続放出用の埋め込み型デバイス
|
|
WO2022256820A1
(en)
*
|
2021-06-03 |
2022-12-08 |
Gensun Biopharma Inc. |
Multispecific antagonists
|
|
AU2022287100A1
(en)
*
|
2021-06-04 |
2024-01-25 |
Innovent Biologics (Suzhou) Co., Ltd. |
Bispecific binding molecule binding vegf and ang2 and use thereof
|
|
CN116265487B
(zh)
*
|
2021-12-16 |
2025-01-10 |
三优生物医药(上海)有限公司 |
抗ang2-vegf双特异性抗体及其用途
|
|
KR20230105972A
(ko)
|
2022-01-05 |
2023-07-12 |
주식회사 카나프테라퓨틱스 |
혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
|
|
CN116925234B
(zh)
*
|
2022-04-02 |
2024-05-31 |
合肥星眸生物科技有限公司 |
一种编码抗vegf-a和ang-2双特异性抗体的aav载体
|
|
WO2023215783A1
(en)
*
|
2022-05-04 |
2023-11-09 |
Kephera Diagnostics, Llc |
Method for detecting lyme disease
|
|
EP4596579A1
(en)
*
|
2022-09-28 |
2025-08-06 |
Kexing Biopharm Co., Ltd. |
Antibody or antigen-binding fragment capable of identifying ang-2, and bispecific antibody for simultaneously identifying vegf and ang-2
|
|
WO2024076993A2
(en)
*
|
2022-10-03 |
2024-04-11 |
Therini Bio, Inc. |
Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|